Financial Ratios

MPS PHARMAA LTD.

NSE : NABSE : 531686ISIN CODE : INE537C01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE1.990 (0 %)
PREV CLOSE ( ) 1.99
OPEN PRICE ( ) 1.99
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 201
TODAY'S LOW / HIGH ( )1.99 1.99
52 WK LOW / HIGH ( ) 1.572.08
NSE
This Company is not listed in NSE
Select year
ParticularsMar2025Mar2024Mar2023Mar2022Mar2021
Operational & Financial Ratios
   Earnings Per Share (Rs)-0.47-0.43-0.55-0.07-2.31
   CEPS(Rs)-0.39-0.36-0.470.19-2.02
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)0.571.031.462.002.07
   Tax Rate(%)-3.942.611.9284.821.73
Margin Ratios
   Core EBITDA Margin(%)-2079.40
   EBIT Margin(%)-2868.33
   Pre Tax Margin(%)-2880.22
   PAT Margin (%)-437.31
   Cash Profit Margin (%)1149.13
Performance Ratios
   ROA(%)-9.32-8.26-10.33-1.32-31.87
   ROE(%)-58.89-34.92-31.75-3.64-71.73
   ROCE(%)-9.70-9.06-11.15-9.64-36.90
   Asset Turnover(x)0.000.000.000.000.00
   Sales/Fixed Asset(x)0.000.000.000.000.00
   Working Capital/Sales(x)0.000.000.00-0.010.00
Efficiency Ratios
   Fixed Capital/Sales(x)485.45
   Receivable days3546.47
   Inventory Days6293.93
   Payable days1303.80769.800.00
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-8.09-8.96-4.447.14-0.37
   Price/Book(x)5.623.121.440.690.36
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)261.01
   EV/Core EBITDA(x)-18.91-19.02-11.66-20.36-1.80
   EV/EBIT(x)-15.69-15.74-10.07-9.10-1.58
   EV/CE(x)1.581.451.130.830.63
   M Cap / Sales82.05
Growth Ratio
   Net Sales Growth(%)-100.00-100.00
   Core EBITDA Growth(%)-1.5823.74-122.6689.45-493.92
   EBIT Growth(%)-1.3120.42-15.2179.32-263.63
   PAT Growth(%)-8.0520.88-641.9096.79-278.50
   EPS Growth(%)-8.0520.89-641.7296.79-278.46
Financial Stability Ratios
   Total Debt/Equity(x)6.903.692.421.521.44
   Current Ratio(x)0.250.270.290.330.33
   Quick Ratio(x)0.190.210.220.240.24
   Interest Cover(x)-685.52-448.07-990.70-241.16-1520.41
   Total Debt/Mcap(x)1.231.191.692.193.96

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.